Suppr超能文献

粪便免疫化学检测和血液检测在有症状患者中对紧急结直肠癌转诊的优先排序:为期 2 年的评估。

Faecal immunochemical testing and blood tests for prioritization of urgent colorectal cancer referrals in symptomatic patients: a 2-year evaluation.

机构信息

Nottingham Colorectal Service, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Eastern Hub, Bowel Cancer Screening Programme, Nottingham University Hospitals NHS Trust, Nottingham, UK.

出版信息

BJS Open. 2021 Mar 5;5(2). doi: 10.1093/bjsopen/zraa056.

Abstract

BACKGROUND

A novel pathway incorporating faecal immunochemical testing (FIT) for rapid colorectal cancer diagnosis (RCCD) was introduced in 2017. This paper reports on the service evaluation after 2 years of pathway implementation.

METHODS

The RCCD protocol was based on FIT, blood results and symptoms to stratify adult patients in primary care. Two-week-wait (2WW) investigation was indicated for patients with rectal bleeding, rectal mass and faecal haemoglobin (fHb) level of 10 µg Hb/g faeces or above or 4 µg Hb/g faeces or more in the presence of anaemia, low ferritin or thrombocytosis, in all other symptom groups. Patients with 100 µg Hb/g faeces or above had expedited investigation . A retrospective audit of colorectal cancer detected between 2017 and 2019 was conducted, fHb thresholds were reviewed and critically assessed for cancer diagnoses.

RESULTS

In 2 years, 14788 FIT tests were dispatched with 13361 (90.4 per cent) completed returns. Overall, fHb was less than 4 µg Hb/g faeces in 9208 results (68.9 per cent), 4-9.9 µg Hb/g in 1583 (11.8 per cent), 10-99.9 µg Hb/g in 1850 (13.8 per cent) and 100 µg Hb/g faeces or above in 720 (5.4 per cent). During follow-up (median 10.4 months), 227 colorectal cancers were diagnosed. The cancer detection rate was 0.1 per cent in patients with fHb below 4 µg Hb/g faeces, 0.6 per cent in those with fHb 4-9.9 µg Hb/g faeces, 3.3 per cent for fHb 10-99.9 µg Hb/g faeces and 20.7 per cent for fHb 100 µg Hb/g faeces or above. The detection rate in the cohort with 10-19.9 µg Hb/g faeces was 1.4 per cent, below the National Institute for Health and Care Excellence threshold for urgent referral. The colorectal cancer rate in patients with fHb below 20 µg Hb/g faeces was less than 0.3 per cent.

CONCLUSION

Use of FIT to "rule out" urgent referral from primary care misses a small number of cases. The threshold for referral may be adjusted with blood results to improve stratification .

摘要

背景

2017 年引入了一种包含粪便免疫化学检测(FIT)的快速结直肠癌诊断(RCCD)新途径。本文报告了该途径实施两年后的服务评估结果。

方法

RCCD 方案基于 FIT、血液结果和症状,对初级保健中的成年患者进行分层。对于有直肠出血、直肠肿块和粪便血红蛋白(fHb)水平为 10μg Hb/g 粪便或以上或贫血、低铁蛋白或血小板增多症患者,fHb 水平为 4μg Hb/g 粪便或以上或以上,则进行两周等待(2WW)调查。在所有其他症状组中,fHb 水平为 100μg Hb/g 粪便或以上的患者需要进行紧急检查。对 2017 年至 2019 年期间检测到的结直肠癌进行了回顾性审核,审查并批判性评估了 fHb 阈值与癌症诊断的关系。

结果

在两年内,共发送了 14788 次 FIT 检测,其中 13361 次(90.4%)完成了返回。总体而言,9208 份结果中 fHb 小于 4μg Hb/g 粪便(68.9%),1583 份结果中 fHb 为 4-9.9μg Hb/g(11.8%),1850 份结果中 fHb 为 10-99.9μg Hb/g(13.8%),720 份结果中 fHb 为 100μg Hb/g 粪便或以上(5.4%)。在随访期间(中位数为 10.4 个月),诊断出 227 例结直肠癌。fHb 低于 4μg Hb/g 粪便的患者癌症检出率为 0.1%,fHb 为 4-9.9μg Hb/g 粪便的患者癌症检出率为 0.6%,fHb 为 10-99.9μg Hb/g 粪便的患者癌症检出率为 3.3%,fHb 为 100μg Hb/g 粪便或以上的患者癌症检出率为 20.7%。fHb 为 10-19.9μg Hb/g 粪便的患者检出率为 1.4%,低于国家卫生与保健卓越研究所(NICE)的紧急转诊阈值。fHb 低于 20μg Hb/g 粪便的患者结直肠癌发生率低于 0.3%。

结论

使用 FIT 来“排除”初级保健中的紧急转诊会遗漏少数病例。可以结合血液结果调整转诊阈值,以改善分层。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae7/7947575/e64b7632cd2d/zraa056f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验